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Abstract
Urocortin (Ucn) peptides are the endogenous ligands for the corticotropin-releasing factor type 2
receptor (CRFR2). They have potentially important roles in cardiovascular physiology in health
and disease, and show promise as therapeutics for congestive heart failure. Analysis of canine
heart tissue showed mRNA expression of Ucn 1, Ucn 3 and CRFR2 in all heart chambers.
Immunohistochemistry also demonstrated Ucn 1 and 3 expression in cardiomyocytes. To assess
the potential usefulness of circulating Ucns as markers of heart disease, plasma samples from 45
dogs with cardiac disease and 15 controls were analysed by radioimmunoassay. Both Ucn 1 and 3
were measurable but the presence of cardiac disease did not alter their concentrations. Therefore,
whilst Ucns are expressed in canine myocardium (where they may play a role in the endogenous
neurohumoral response to cardiac disease or failure) they do not appear to be sensitive biomarkers
of cardiac disease in our canine patient population.
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Introduction
Urocortins (Ucns 1, 2 and 3) are peptide hormones (Vaughan et al., 1995; Hsu and Hsueh,
2001; Lewis et al., 2001; Reyes et al., 2001) structurally and biologically related to
corticotropin-releasing factor (CRF) (Fekete and Zorrilla, 2007). In contrast to CRF, Ucns
are expressed in peripheral tissues including the heart and vasculature (Baigent and Lowry,
2000; Hsu and Hsueh, 2001; Lewis et al., 2001) and are under investigation as therapeutic
agents for heart failure. Ucns protect cardiomyocytes from hypoxic injury in experimental
myocardial ischemia reperfusion models (Brar et al., 2004; Lawrence et al., 2004), and
increase cardiac output via potent positive inotropic actions. Beneficial effects of Ucns are
observed in animal models of heart failure (Parkes et al., 1997; Bale et al., 2004; Rademaker
et al., 2005a, b; Rademaker et al., 2006).
The role of endogenous Ucns in the pathophysiology of heart failure is unknown.
Expression of Ucn peptides has been demonstrated in rodent (Okosi et al., 1998; Pournajafi-
Nazarloo et al., 2007) and human hearts (Hsu and Hsueh, 2001; Kimura et al., 2002;
Takahashi et al., 2004). Plasma concentrations of Ucn 1 are increased in human heart failure
patients (Ng et al., 2004; Wright et al., 2009; Gruson et al, 2010), and sheep with
experimentally-induced heart failure also have increased circulating levels (Charles et al.,
2006). Endogenous concentrations of Ucns 2 and 3 have not been described in heart failure.
The CRF receptor type 2 (CRFR2) is specific for Ucn signalling and is expressed in
peripheral tissues including heart and vasculature (Kishimoto et al., 1995; Perrin et al.,
1995). Several receptor isoforms exist (CRFR2α, β, γ) and their localisation varies with
species and tissue. In man, CRFR2α is present in all heart chambers, whereas CRFR2β
expression is restricted to the atria (Kimura et al., 2002). In rodents, CRFR2β is the major
isoform in heart (Lovenberg et al., 1995; Nishikimi et al., 2000). No studies on the
expression of Ucns or CRFR2 have been performed in the dog.
Given the importance of canine heart failure in veterinary practice and the current interest in
Ucns as potential therapeutics for cardiac conditions, we have characterised the expression
of Ucns and CRFR2 in the dog heart. We also determined plasma Ucn levels in dogs with
heart disease and controls to assess their potential usefulness as a marker of heart disease in
this species.
Materials and methods
Heart tissue sample collection
Studies were approved by the University of Edinburgh Ethics Committee. Cardiac tissues
were obtained from healthy dogs euthanased for behavioural reasons, with no history or
evidence of cardiovascular disease on ante-mortem clinical examination. Estimated ages
ranged from 18 months to 10 years. There were four entire female and four entire male dogs.
Breeds were two terrier-cross, one Staffordshire Bull terrier, two Staffordshire Bull terrier-
cross, one Yorkshire terrier, one Rottweiler and one cross-breed dog. Tissues were collected
within 30-60 min of euthanasia from the following standardised sites: right atrium (RA),
right ventricular free wall (RVFW), left atrium (LA), left ventricular free wall (LVFW),
interventricular septum (IVS) and left ventricular papillary muscle (LVPM). All tissues were
macroscopically normal. Tissue for mRNA extraction was collected in RNAlater (Ambion),
stored at 4 °C for 24 h and then −80 °C until analysis. Tissue for immunohistochemistry was
stored at −80 °C until sectioning.
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Plasma sample collection and heart disease classification
Plasma was obtained from 45 dogs investigated for cardiac diseases at the University of
Edinburgh Hospital for Small Animals (UK) and the Koret School of Veterinary Medicine
(Israel) with owner consent. There were 24 males, 3 neutered males, 9 females, and 9
neutered females. Ages ranged from 9 months to 15 years (mean 7.9 years). Control plasma
was from 15 dogs with non-critical non-cardiac diseases comprising 5 males, 3 neutered
males, 1 female, 6 neutered females, with ages raging from 1 to 13 years (mean 5.8 years).
Blood was collected by jugular venepuncture into EDTA collection tubes, separated by
centrifugation, and plasma stored at −80 °C until analysis.
Dogs with cardiac disease were characterised by clinical examination, thoracic radiography,
electrocardiography and two-dimensional and colour-flow Doppler echocardiography.
Diagnoses were as follows: dilated cardiomyopathy (DCM) (n = 15), mitral valve disease
(MVD) (n = 18), subaortic stenosis (SAS) (n = 6), or ‘other’ cardiac disease (pericardial
effusion n = 1, third degree AV block n = 1, tricuspid dysplasia n = 1, patent ductus
arteriosus n = 1, primary supraventricular tachycardia n = 1, heart base tumour n = 1). MVD
was defined as a systolic heart murmur of grade 3/6 or greater over the left apex with
fractional shortening (FS) > 30%. SAS was classified as velocity > 2.5 m/s. DCM was
defined as a systolic heart murmur grade 3/6 or less over the left apex with FS < 25%.
RNA analysis
Total RNA was isolated with Trizol (Ambion), digested with RNase-Free DNase (Qiagen)
and reverse transcribed (RT) to generate cDNA (SuperScript II, Invitrogen). Primers (Table
1) were designed from published nucleotide sequences in the Ensembl database. CRFR2α
and CRFR2β PCRs amplified sequence spanning an intron. S16 was used as a housekeeping
gene. Genomic DNA from canine liver was included as a positive control for Ucn PCRs. RT
negative controls were included for all reactions.
The GC-RICH PCR System (Roche) was used for RT-PCR for Ucns and CRFR2.
Conditions for Ucn 2, Ucn 3 and CRFR2β were as follows: 50 μL reaction with 1X GC-Rich
Buffer, 0.2 mM dNTP, 2.5 mM MgCl2, 0.4 μM sense primer, 0.4 μM antisense primer, 2U
GC-Rich Taq, cDNA equivalent to 25 ng tRNA (1μL) and PCR cycling 95 °C 3 min, then
95 °C 30 s, 56 °C 30 s, 72 °C 1 min for 40 cycles, and a final elongation step 72 °C for 7
min. For Ucn 1 and CRFR2α conditions were as follows: 50 μL reaction with 1X GC-Rich
Buffer, 0.2 mM dNTP, 5 mM MgCl2, 5% DMSO, 0.8 μM sense primer, 0.8 μM antisense
primer, 1 μL GC-Rich Taq, 1 μL cDNA and cycled as above with annealing temperature 58
°C. For S16 conditions were: 50 μL reaction with 1X Hotmaster Taq buffer, 0.2 mM dNTP,
0.4 μM sense primer, 0.4 μM antisense primer, 1U Hotmaster Taq Polymerase (Eppendorf),
1 μL cDNA, cycled as above for 30 cycles with annealing temperature of 58 °C.
Amplification products were subjected to electrophoresis in a 2% agarose gel, stained with
ethidium bromide and photographed under UV illumination. PCR products were purified
(High Pure PCR Product Purification kit, Roche) and submitted for DNA sequencing to
verify specificity of product.
Immunohistochemistry
The LVFW and LA of four dogs were analysed. Ucn antisera were raised in rabbit (The Salk
Institute; anti-Ucn 1 PBL 5779, anti-Ucn 2 6488, anti-Ucn 3 6570). Frozen tissue sections (5
μm) were fixed in ice-cold acetone 10 min, washed 3X in PBS 5 min, blocked with Protein
Block (DAKO Corp) 10 min, washed briefly, blocked with goat serum 20 min at room
temperature, incubated with primary antibody at 1:50 concentration in DAKO antibody
diluent at room temperature for 1 h, washed 3X in PBS for 5 min, blocked again with sera
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for 10 min, incubated with HRP goat anti-rabbit antibodies for 30 min at room temperature,
and the PBS washes were repeated. Sections were then incubated with a diaminobenzidine
solution and finally washed with water. A light haematoxylin counterstain was performed,
and sections dehydrated with ascending grades of alcohol, cleared in xylene and mounted in
Pertex.
Urocortin radioimmunoassays
Ucn 1 and Ucn 3 were measured in plasma using RIAs we developed and with a protocol
similar to that for inhibin subunits (Vaughan et al., 1989). Samples were acidified and
extracted as described, except elution of octadecyl silica cartridges was with 75%
acetonitrile/25% triethylammonium formate, pH 3.0 (Vale et al., 1986). For Ucn 1 RIA,
rabbit anti-rat Ucn 1 serum (PBL 5779) was used at 1:700,000 final dilution, with [125
I]DTyr° rUcn 1 used as tracer, and rUcn 1 as standard. For Ucn 3 RIA, rabbit anti-mouse
TyrGlyUcn 3 serum (PBL 6598) was used at a 1:75,000 final dilution, [125I]Tyr0Nle12,35
mUcn 3 was the tracer, and mUcn 3 was used as standard. Samples were tested at two dose
levels. Free tracer was separated from antibody-bound tracer with sheep anti-rabbit γ-
globulins and 10% (wt/vol) polyethylene glycol. Results were calculated using a logit/log
RIA data processing program.
The EC50 and minimum detectable dose per tube were 30 pg and 1.5 pg for Ucn 1, and 25
pg and 2 pg for Ucn 3, respectively. This corresponds to a minimal detectable level of 0.5
pmol/L for Ucn 1 and 0.8 pmol/L for Ucn 3 in samples. Closely related CRF peptide family
members r/h CRF, hUcn 2, mUcn 2, hUcn 3, and mUcn 3 at doses to 100 ng/tube failed to
displace the tracer in the rUcn 1 RIA. The mUcn 3 RIA is highly specific for the murine Ucn
3 homolog and cross-reactivity with related peptides has been previously reported (Li et al.,
2003).
Statistical analysis
Statistical analysis was performed with Minitab 15 for Windows. Ucn 1 and Ucn 3
concentrations below the lowest detectable limit of the assay were ascribed a value just over
half the limit (Ucn 1, 0.27 pmol/L; Ucn 3, 0.48 pmol/L) for analysis. Data were assessed
graphically and with the Kolmogorov-Smirnov test, and were found not to be normally
distributed. Therefore, the Kruskal-Wallis test was used to make comparisons between the
cardiac disease and the control groups. Statistical significance was set at P < 0.05. Data are
displayed as the median (minimum/maximum) concentrations.
Results
Ucn peptide sequences
A species comparison between the published precursor and predicted mature peptide
sequences of canine Ucns (1, 2 and 3) is presented in Tables 2 and 3. Canine Ucn 1 shows
93% and 98% homology to the human and mouse peptides, respectively (Table 3), whilst
Ucn 3 has 92% homology to both human and mouse sequences. Canine Ucn 2 is 76%
homologous to murine Ucn 2 but has 92% homology with human Ucn 2. Notably, the canine
Ucn 2 precursor has a glycine residue followed by two basic amino acids at the C-terminus,
which could be predicted to allow amidation and cleavage to a 38 amino acid peptide like in
rodents.
mRNA expression of Ucns and CRFR2 in canine heart
mRNA expression of all three Ucns was demonstrated in canine heart (Fig. 1). Ucn 3 was
the major transcript with robust expression in all cardiac tissues at similar levels. Ucn 1 and
Ucn 2 were expressed at barely detectable levels. However, while Ucn 1 mRNA was
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variably present in all heart regions, Ucn 2 mRNA showed higher levels in RA of 3/4 dogs.
The CRFR2α splice variant was expressed in all cardiac tissues with no clear differences in
regional distribution. However, CRFR2β expression was clearly higher in atrial tissue and
weak elsewhere (LVFW, RVFW, IVS and LVPM) (Fig. 1).
Immunohistochemistry
Ucn 1 positive staining occurred intracellularly throughout atrial and ventricular
myocardium as discreet round or irregular foci, usually in close proximity with
cardiomyocyte nuclei (Fig. 2). Staining was more abundant in ventricular tissue. Specific
Ucn 1 staining appeared to be outside of nuclei or on the nuclear membrane surface, often
localised to one nuclear pole (Fig. 3a). Additionally, there were often smaller bands of
staining perpendicular to the long axis of cardiomyocyte nuclei (Fig. 3b). The apparent
perinuclear (rather than intranuclear) localisation of Ucn 1 was obvious in sectional planes
where the Ucn 1-positive staining clearly extended beyond the haematoxylin-stained nuclear
boundaries (Fig. 3c). Irregular, asymmetrical granular Ucn 1 staining, apparently adjacent to
cardiomyocyte nuclear membranes was also commonly seen (Fig. 3d).
Ucn 3 positive staining occurred throughout the atrial and ventricular myocardium in three
patterns. The most abundant pattern was uniform, short linear structures, which appeared to
be within the endomysium and not within cardiomyocytes (Fig. 4). The second pattern was
uniform cytoplasmic staining of stellate or fusiform cells within the endomysium. The least
abundant pattern was within cardiomyocytes adjacent to nuclei. Rarely, the first pattern
(short linear endomysial) could be resolved into two parallel lines or triangles around a
central lumen suggesting that most or all of this was cytoplasmic staining of capillary
endothelial cells (Fig. 5a) but inadequate resolution of cryostat sections precluded
confirmation of this. Specific Ucn 3 perinuclear staining resembled that seen for Ucn 1,
being localised eccentrically adjacent to the nucleus (Fig. 5b). No positive staining for Ucn 2
was seen in any sections (data not shown).
Plasma concentrations of Ucn 1 and Ucn 3
Ucn 1 and Ucn 3 were measurable in plasma from dogs with cardiac disease and controls
(Fig. 6). Ucn 1 was detectable in all control dogs (median level 1.71 [range: 1.08-7.92]
pmol/L), and in 39/35 dogs with cardiac disease (median level 1.59 [0.42-7.33] pmol/L). In
contrast, Ucn 3 was below the assay detection level in 11/15 control dogs (median 0.48
[0.48-4.01] pmol/L) and 18/45 dogs with cardiac disease (median 0.48 [0.48-4.76] pmol/L).
There was no statistical difference between the levels of Ucn 1 or Ucn 3 in controls and dogs
with cardiac disease (Fig. 6). The numbers in this study did not allow for an adequately
powered statistical analysis comparing specific cardiac conditions or class of heart failure,
and no evidence of a trend for differences in Ucn levels was observed when data were
categorised in this manner (data not shown).
Discussion
While Ucn 1 and Ucn 3 peptides are highly conserved across species, Ucn 2 is more
divergent and canine Ucn 2 shows higher homology to human Ucn 2 than rodent Ucn 2.
However, unlike human Ucn 2, which lacks a consensus proteolytic cleavage site for C-
terminal processing to the bioactive peptide (Reyes et al., 2001), the canine Ucn 2 sequence
is predicted to produce a bioactive peptide. Nevertheless, Ucn 1 and Ucn 3 are the main
mRNA transcripts in canine heart, with only barely detectable Ucn 2 mRNA levels present
in the right atrium. As in humans, CRFR2α is expressed throughout the heart, while
CRFR2β is expressed at higher levels in atrial tissue (Kimura et al., 2002). The significance
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of these species-specific patterns of expression is unclear but probably represents
evolutionary selection of ligands for CRFR2.
Immunohistochemistry was consistent with mRNA expression, with Ucn 1 and Ucn 3
detected in cardiomyocytes. Stronger immunostaining for Ucn 1 in contrast to the PCR
results is most likely due to relative differences in antibody affinities and PCR reaction
efficiencies. The cellular distribution of Ucn positive immunostaining is interesting.
Detailed ultrastructural studies are needed to definitively identify the Ucn immunoreactive
subcellular structures, but the perinuclear staining is consistent with distribution in the Golgi
apparatus of cardiomyocytes (Kobayashi et al., 2006), and with previous reports of Ucn 1
localisation in neurons (Kozicz et al., 2002; Swinny et al., 2002). Ucn 3 was also present in
structures which may represent endothelial cells, a known target for CRFR2 action
(Davidson and Yellon, 2009) which express mRNAs for Ucns (Kageyama et al., 2009).
Having established that Ucn 1 and Ucn 3 are expressed in the canine heart, we measured
circulating concentrations in dogs with cardiac disease. Clearly if these potent regulators of
cardiovascular physiology are expressed endogenously, their concentrations may be altered
by cardiac disease or stress. This has been demonstrated for Ucn 1 in experimental heart
failure models (Nishikimi et al., 2000; Charles et al., 2006) and in clinical studies in humans
(Ng et al., 2004; Wright et al., 2009; Gruson et al., 2010). However, the results of these
studies have shown that Ucn 1 is an inferior biomarker of heart failure to NT-proBNP
(Wright et al., 2009) and that concentrations do not correlate significantly with other well
established heart failure biomarkers (Gruson et al., 2010). Trans-organ arteriovenous
sampling in sheep has suggested Ucn 1 release from kidney, brain, liver and/or
gastrointestinal tract, but surprisingly not from cardiac tissue either normally or in heart
failure (Takahashi et al., 2004; Charles et al., 2006). Thus, the site of production of
circulating Ucns may be a significant confounding factor.
We found that whereas both Ucn 1 and Ucn 3 were measurable in canine plasma,
concentrations were highly variable both in dogs with heart disease and in control dogs and
that considerable overlap exists with no significant difference between the two populations.
While it is possible that increasing sample numbers may have detected altered Ucn
concentrations, and that Ucn expression is altered in canine heart disease at the tissue level,
our aim was to assess the usefulness of Ucns as clinical markers for cardiac disease. Ucns
may be relevant to the cardiac humoral response to heart failure and modulate
cardiovascular functions in health and disease but studies correlating circulating Ucn levels
and heart function (including the current work) demonstrate a lack of sensitivity, and Ucns
are unlikely to be useful biomarkers for cardiac disease or function or offer any advantage
over serum natriuretic peptides.
Conclusions
Ucn 1 and Ucn 3 are expressed in canine heart tissue and are measurable in canine plasma
but they do not appear to be sensitive biomarkers of cardiac disease in the canine population
evaluated in this study.
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Fig. 1. RT-PCR analysis for Ucns and CRFR2 isoforms in canine cardiac tissue
RA, right atrium; RV, right ventricle; LA, left atrium; LV, left ventricle; IVS,
interventricular septum; PM, left ventricular papillary muscle; -RT, tRNA subjected to the
RT protocol without reverse transcriptase enzyme. S16 was used as an internal control.
Genomic DNA was used as a positive control for Ucn PCR reactions.
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Fig. 2. Anti-Ucn 1 immunohistochemistry of canine ventricular myocardium
Discreet foci of Ucn 1 positive staining are seen in ventricular (A) and atrial (C) tissue. No
staining occurred in ventricular (B) and atrial (D) tissue incubated with control non-immune
rabbit serum. Representative image, size bars are 10 μm, light haematoxylin counterstain.
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Fig. 3. Anti-Ucn 1 immunohistochemistry of canine ventricular myocardium
(A) A round focus of Ucn 1-positive staining (arrows) adjacent to one pole of a
haematoxylin stained cardiomyocyte nucleus. (B) Associated with a cardiomyocyte nucleus
is a prominent focus of peripolar staining (left arrow) and several small bands of Ucn 1-
positive staining perpendicular to the long axis of the nucleus (other arrows). (C) Ucn 1-
positive staining (red arrows) extends beyond the boundaries of the cardiomyocyte nucleus
(green arrows). (D) Irregular, random granular Ucn 1-positive staining appears to be
adherent to a cardiomyocyte nucleus (N). Representative image, size bars are 4 μm, light
haematoxylin counterstain.
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Fig. 4. Anti-Ucn 3 immunohistochemistry of canine ventricular myocardium
Ucn 3-positive staining is seen in ventricular (A) and atrial (C) tissue. No staining occurred
in ventricular (B) and atrial (D) tissue incubated with control non-immune rabbit serum.
Three patterns of Ucn 3-positive staining are discerned. The first is short linear structures,
which appear to be in the endomysium (single red arrows). The second is diffuse
cytoplasmic staining of fusiform or stellate cells within the endomysium (double red
arrows). The third is perinuclear within cardiomyocytes (green arrows). Representative
image, size bars are 10 μm, light haematoxylin counterstain.
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Fig. 5. Anti-Ucn 3 immunohistochemistry of canine ventricular myocardium
(A) Ucn 3-positive staining of an apparent capillary endothelial cell. (B) Ucn 3-positive
staining adjacent to a haematoxylin counterstained cardiomyocyte nucleus (red arrows).
Representative image, size bars are 4 μm, light haematoxylin counterstain.
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Fig.6.
Plasma concentrations of (A) Ucn 1 and (B) Ucn 3 (pmol/L) in dogs with cardiac disease (n
= 45) and a control group (n = 15). Data are presented as a dot plot where X represents the
median value.
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Table 1
PCR primers sequences used in this study.
Gene Transcript ID Primer Sequence Product
UCN 1 ENSCAFT0000003593
7
Sense
Antisens
e
5′-AGGACCCAAGTCTGCGCTA
5′-
CGAATATGATGCGGTTCTGCTC
258 bp
UCN 2 ENSCAFT0000001979
0
Sense
Antisens
e
5′-ATGACCAGGTGGGCTTTG
5′-GTTGGTGGTGGCCTGCTC
306 bp
UCN 3 ENSCAFT0000000847
3
Sense
Antisens
e
5′-
CAGAAGTTCCACCCAGGAAA
5′-GTATTTGTACCGGGCGCTTA
240 bp
CRFR2α ENSCAFT0000000497
1
Sense
Antisens
e
5′-AGGAGCTGCTCCTGGACGG
5′-TGCGGTAGTGCAGGTCATAC
285 bp
CRFR2β ENSCAFT0000000497
2
Sense
Antisens
e
5′-GAGCCAGGCGCAGATACAT
5′-
AAACGCAGTGACCCAGGTAG
356 bp
S16 ENSCAFT0000000550
1
Sense
Antisens
e
5′-CAAGGGTCCTCTGCAGTCC
5′-GTCCCATGACAGCGGTTTAT
485 bp
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Table 2
Canine urocortin precursor peptide sequences. Underlined regions represent the predicted mature peptide
sequence.
Peptide Sequence
UCN 1
MKQRGRAALLMALLLLAQLRPGSSQWSREAAAAGVQDPSLRWNPGARNQDGGARAL
LLLLAERFPRRAGPGRWGSRTAGERPRRDDPPLSIDLTFHLLRTLLELARTQSQRERAEQ
NRIIFESVGK
UCN 2
MTRWALLVLMVLTSGRALLVTGTPSPAFQLLPQNPPQATPCPVTSESTTATTTGPSTAW
G HPSPGPRSGPRIILSLDVPIGLLQILLEQARARASREQATTNARILAQVGRR
UCN 3
MLMPAYLLLLLLLLPGIPQPGLSQKFHPGKSFFSCINTALWEARQSPLEDAPLLSKRSFPY
LPSQDPSSGEDEEKEEEEEDKKKRTFPGFGGGNGAVSARYKYLSPAQLKGRLHQDKAKS
DRRTKFTLSLDVPTNIMNILFNIAKAKNLQAKAAANAHLMAQIGRKK
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Table 3
Homology of canine urocortin peptides to mouse and human homologues. Boxed residues differ from the
canine sequences.
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